-
1
-
-
84930607509
-
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
-
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 3-15
-
-
Smolen, J.S.1
Breedveld, F.C.2
Burmester, G.R.3
Bykerk, V.4
Dougados, M.5
Emery, P.6
-
2
-
-
84893772728
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
-
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 492-509
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
Buch, M.4
Burmester, G.5
Dougados, M.6
-
3
-
-
84893731584
-
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
-
Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536–43.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 536-543
-
-
Takeuchi, T.1
Yamanaka, H.2
Ishiguro, N.3
Miyasaka, N.4
Mukai, M.5
Matsubara, T.6
-
4
-
-
84954360828
-
The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor-prognostic factors, C-OPERA, shows inhibition of radiographic progression
-
Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor-prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016;75:75–83.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 75-83
-
-
Atsumi, T.1
Yamamoto, K.2
Takeuchi, T.3
Yamanaka, H.4
Ishiguro, N.5
Tanaka, Y.6
-
5
-
-
45349090538
-
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
-
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.
-
(2008)
Arthritis Rheum
, vol.59
, pp. 762-784
-
-
Saag, K.G.1
Teng, G.G.2
Patkar, N.M.3
Anuntiyo, J.4
Finney, C.5
Curtis, J.R.6
-
6
-
-
0028223097
-
Methotrexate serum binding in rheumatoid arthritis
-
Claudepierre P, Urien S, Chevalier X, Chassany O, Larget-Piet B, Tillement JP., Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharmacol Ther. 1994;32:113–15.
-
(1994)
Int J Clin Pharmacol Ther
, vol.32
, pp. 113-115
-
-
Claudepierre, P.1
Urien, S.2
Chevalier, X.3
Chassany, O.4
Larget-Piet, B.5
Tillement, J.P.6
-
7
-
-
84891907570
-
JSH guidelines for the management of hepatitis B virus infection
-
Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(S1):1–58.
-
(2014)
Hepatol Res
, vol.44
, Issue.S1
, pp. 1-58
-
-
-
8
-
-
33745819196
-
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
-
Pavy S, Constantin A, Pham T, Gosseec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.
-
(2006)
Joint Bone Spine
, vol.73
, pp. 388-395
-
-
Pavy, S.1
Constantin, A.2
Pham, T.3
Gosseec, L.4
Maillefert, J.F.5
Cantagrel, A.6
-
9
-
-
67549096874
-
Multinational evidence-based recommendations for the arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
-
Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–93.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1086-1093
-
-
Visser, K.1
Katchamart, W.2
Loza, E.3
Martinez-Lopez, J.A.4
Salliot, C.5
Trudeau, J.6
-
10
-
-
14544292345
-
Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis
-
Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Jpn J Inflammat. 1996;16:437–58.
-
(1996)
Jpn J Inflammat
, vol.16
, pp. 437-458
-
-
Kashiwazaki, S.1
Ichikawa, Y.2
Sugawara, S.3
Nagaya, I.4
Kawai, S.5
Hakota, M.6
-
11
-
-
67549101312
-
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
-
Visser K, van der Heijde D., Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68:1094–9.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1094-1099
-
-
Visser, K.1
van der Heijde, D.2
-
12
-
-
84855911986
-
Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review
-
Mouterde G, Baillet A, Gaujoux-Viala C, Cantagrel A, Wendling D, Le Loët X, et al. Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78:587–92.
-
(2011)
Joint Bone Spine
, vol.78
, pp. 587-592
-
-
Mouterde, G.1
Baillet, A.2
Gaujoux-Viala, C.3
Cantagrel, A.4
Wendling, D.5
Le Loët, X.6
-
13
-
-
0021709870
-
A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
-
Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS., A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11:760–3.
-
(1984)
J Rheumatol
, vol.11
, pp. 760-763
-
-
Thompson, R.N.1
Watts, C.2
Edelman, J.3
Esdaile, J.4
Russell, A.S.5
-
14
-
-
84860736264
-
A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis
-
Hobl EL, Mader RM, Jilma B, Duhm B, Mustak M, Bröll H, et al. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis. Clin Ther. 2012;34:1195–203.
-
(2012)
Clin Ther
, vol.34
, pp. 1195-1203
-
-
Hobl, E.L.1
Mader, R.M.2
Jilma, B.3
Duhm, B.4
Mustak, M.5
Bröll, H.6
-
15
-
-
84918571233
-
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomized, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
-
Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomized, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 19-26
-
-
Emery, P.1
Burmester, G.R.2
Bykerk, V.P.3
Combe, B.G.4
Furst, D.E.5
Barré, E.6
-
16
-
-
84946887746
-
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
-
Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081–91.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 1081-1091
-
-
Burmester, G.R.1
Rigby, W.F.2
van Vollenhoven, R.F.3
Kay, J.4
Rubbert-Roth, A.5
Kelman, A.6
-
17
-
-
0033596065
-
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group
-
Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50.
-
(1999)
Arch Intern Med
, vol.159
, pp. 2542-2550
-
-
Strand, V.1
Cohen, S.2
Schiff, M.3
Weaver, A.4
Fleischmann, R.5
Cannon, G.6
-
18
-
-
3242677099
-
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
-
Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.
-
(2004)
Lancet
, vol.364
, pp. 263-269
-
-
Grigor, C.1
Capell, H.2
Stirling, A.3
McMahon, A.D.4
Lock, P.5
Vallance, R.6
-
19
-
-
35648991026
-
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
-
Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443–9.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1443-1449
-
-
Verstappen, S.M.1
Jacobs, J.W.2
van der Veen, M.J.3
Heurkens, A.H.4
Schenk, Y.5
ter Borg, E.J.6
-
20
-
-
0027305420
-
Methotrexate-the relationship between dose and clinical effect
-
Seideman P. Methotrexate-the relationship between dose and clinical effect. Br J Rheumatol. 1993;32:751–3.
-
(1993)
Br J Rheumatol
, vol.32
, pp. 751-753
-
-
Seideman, P.1
-
21
-
-
4644275370
-
Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis
-
Wegrzyn J, Adeleine P, Miossec P., Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232–4.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1232-1234
-
-
Wegrzyn, J.1
Adeleine, P.2
Miossec, P.3
-
23
-
-
1842425908
-
Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis
-
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M., Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645–8.
-
(2004)
J Rheumatol
, vol.31
, pp. 645-648
-
-
Hoekstra, M.1
Haagsma, C.2
Neef, C.3
Proost, J.4
Knuif, A.5
van de Laar, M.6
-
24
-
-
1842574679
-
Bioavailability and pharmacokinetics of methotrexate (MTX) and its metabolite 7-hydroxy MTX after low dose MTX (25 mg) in patients with chronic rheumatic diseases
-
Korber H, Iven H, Gross WL., Bioavailability and pharmacokinetics of methotrexate (MTX) and its metabolite 7-hydroxy MTX after low dose MTX (25 mg) in patients with chronic rheumatic diseases. Arthritis Rheum. 1992;35(l):S142.
-
(1992)
Arthritis Rheum
, vol.35
, pp. S142
-
-
Korber, H.1
Iven, H.2
Gross, W.L.3
-
25
-
-
0016656293
-
Comparison of serum concentrations of methotrexate after various routes of administration
-
Freeman-Narrod M, Gerstley BJ, Engstrom PF, Bomstein RS., Comparison of serum concentrations of methotrexate after various routes of administration. Cancer. 1975;36:1619–24.
-
(1975)
Cancer
, vol.36
, pp. 1619-1624
-
-
Freeman-Narrod, M.1
Gerstley, B.J.2
Engstrom, P.F.3
Bomstein, R.S.4
-
26
-
-
0023195465
-
Methotrexate bioavailability after oral and intramuscular administration in children
-
Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE., Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987;110:788–92.
-
(1987)
J Pediatr
, vol.110
, pp. 788-792
-
-
Teresi, M.E.1
Crom, W.R.2
Choi, K.E.3
Mirro, J.4
Evans, W.E.5
-
27
-
-
38149057526
-
Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial
-
Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 73-81
-
-
Braun, J.1
Kästner, P.2
Flaxenberg, P.3
Währisch, J.4
Hanke, P.5
Demary, W.6
-
28
-
-
84903893560
-
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration
-
Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 1549-1551
-
-
Schiff, M.H.1
Jaffe, J.S.2
Freundlich, B.3
-
29
-
-
33644681620
-
Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis
-
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M., Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:481–5.
-
(2006)
J Rheumatol
, vol.33
, pp. 481-485
-
-
Hoekstra, M.1
Haagsma, C.2
Neef, C.3
Proost, J.4
Knuif, A.5
van de Laar, M.6
-
30
-
-
84957582274
-
Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration
-
Bianchi G, Caporali R, Todoerti M, Mattana P., Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33:369–78.
-
(2016)
Adv Ther
, vol.33
, pp. 369-378
-
-
Bianchi, G.1
Caporali, R.2
Todoerti, M.3
Mattana, P.4
-
31
-
-
84956767541
-
2015 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis
-
Singh JA, Saag SK, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
-
(2016)
Arthritis Rheumatol
, vol.68
, pp. 1-26
-
-
Singh, J.A.1
Saag, S.K.2
Bridges, S.L.3
Akl, E.A.4
Bannuru, R.R.5
Sullivan, M.C.6
-
32
-
-
78650569574
-
Drug combinations with methotrexate to treat rheumatoid arthritis
-
Rath T, Rubbert A., Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(61):S52–S7.
-
(2010)
Clin Exp Rheumatol
, vol.28
, Issue.61
, pp. S52-S7
-
-
Rath, T.1
Rubbert, A.2
-
33
-
-
34547589468
-
Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs
-
Dale J, Alcorn N, Capell H, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol. 2007;3:450–8.
-
(2007)
Nat Clin Pract Rheumatol
, vol.3
, pp. 450-458
-
-
Dale, J.1
Alcorn, N.2
Capell, H.3
Madhok, R.4
-
34
-
-
0029022389
-
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group
-
Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137–41.
-
(1995)
N Engl J Med
, vol.333
, pp. 137-141
-
-
Tugwell, P.1
Pincus, T.2
Yocum, D.3
Stein, M.4
Gluck, O.5
Kraag, G.6
-
35
-
-
0344237251
-
Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone
-
Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S., Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford). 2003;42:1545–9.
-
(2003)
Rheumatology (Oxford)
, vol.42
, pp. 1545-1549
-
-
Marchesoni, A.1
Battafarano, N.2
Arreghini, M.3
Panni, B.4
Gallazzi, M.5
Tosi, S.6
-
36
-
-
33846864259
-
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
-
Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66:235–41.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 235-241
-
-
Capell, H.A.1
Madhok, R.2
Porter, D.R.3
Munro, R.A.4
McInnes, I.B.5
Hunter, J.A.6
-
37
-
-
0032957015
-
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
-
Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–5.
-
(1999)
Ann Rheum Dis
, vol.58
, pp. 220-225
-
-
Dougados, M.1
Combe, B.2
Cantagrel, A.3
Goupille, P.4
Olive, P.5
Schattenkirchner, M.6
-
38
-
-
0028572390
-
Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy
-
Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van’t Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol.1994;33:1049–55.
-
(1994)
Br J Rheumatol
, vol.33
, pp. 1049-1055
-
-
Haagsma, C.J.1
van Riel, P.L.2
de Rooij, D.J.3
Vree, T.B.4
Russel, F.J.5
van’t Hof, M.A.6
-
39
-
-
0030696346
-
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial
-
Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082–8.
-
(1997)
Br J Rheumatol
, vol.36
, pp. 1082-1088
-
-
Haagsma, C.J.1
van Riel, P.L.2
de Jong, A.J.3
van de Putte, L.B.4
-
40
-
-
0037027427
-
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
-
Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726–33.
-
(2002)
Ann Intern Med
, vol.137
, pp. 726-733
-
-
Kremer, J.M.1
Genovese, M.C.2
Cannon, G.W.3
Caldwell, J.R.4
Cush, J.J.5
Furst, D.E.6
-
41
-
-
18644373869
-
A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study
-
Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005;52:1360–70.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 1360-1370
-
-
Lehman, A.J.1
Esdaile, J.M.2
Klinkhoff, A.V.3
Grant, E.4
Fitzgerald, A.5
Canvin, J.6
-
42
-
-
0142135694
-
Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study
-
Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 2763-2768
-
-
Kremer, J.M.1
Habros, J.S.2
Kolba, K.S.3
Kaine, J.L.4
Borton, M.A.5
Mengle-Gaw, L.J.6
-
43
-
-
84880816170
-
Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate
-
Kitahama M, Nakajima A, Inoue E, Taniguchi A, Momohara S, Yamanaka H, et al. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. Mod Rheumatol. 2013;23:788–93.
-
(2013)
Mod Rheumatol
, vol.23
, pp. 788-793
-
-
Kitahama, M.1
Nakajima, A.2
Inoue, E.3
Taniguchi, A.4
Momohara, S.5
Yamanaka, H.6
-
44
-
-
84877732792
-
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
-
Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23:430–9.
-
(2013)
Mod Rheumatol
, vol.23
, pp. 430-439
-
-
Ishiguro, N.1
Yamamoto, K.2
Katayama, K.3
Kondo, M.4
Sumida, T.5
Mimori, T.6
-
45
-
-
84900384454
-
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial
-
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24:410–18.
-
(2014)
Mod Rheumatol
, vol.24
, pp. 410-418
-
-
Hara, M.1
Ishiguro, N.2
Katayama, K.3
Kondo, M.4
Sumida, T.5
Mimori, T.6
-
46
-
-
70349785354
-
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis
-
Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1069–72.
-
(2009)
Rheumatology (Oxford)
, vol.48
, pp. 1069-1072
-
-
Sawada, T.1
Inokuma, S.2
Sato, T.3
Otsuka, T.4
Saeki, Y.5
Takeuchi, T.6
-
47
-
-
27744516900
-
Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study
-
Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323–8.
-
(2005)
Mod Rheumatol
, vol.15
, pp. 323-328
-
-
Ichikawa, Y.1
Saito, T.2
Yamanaka, H.3
Akizuki, M.4
Kondo, H.5
Kobayashi, S.6
-
48
-
-
84893721202
-
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
-
Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–28.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 516-528
-
-
Nam, J.L.1
Ramiro, S.2
Gaujoux-Viala, C.3
Takase, K.4
Leon-Garcia, M.5
Emery, P.6
-
49
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
-
Klareskog L, vander Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.
-
(2004)
Lancet
, vol.363
, pp. 675-681
-
-
Klareskog, L.1
vander Heijde, D.2
de Jager, J.P.3
Gough, A.4
Kalden, J.5
Malaise, M.6
-
50
-
-
79961102216
-
Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study
-
Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38:1585–92.
-
(2011)
J Rheumatol
, vol.38
, pp. 1585-1592
-
-
Kameda, H.1
Kanbe, K.2
Sato, E.3
Ueki, Y.4
Saito, K.5
Nagaoka, S.6
-
51
-
-
31044442965
-
The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
Cohen, S.B.4
Pavelka, K.5
van Vollenhoven, R.6
-
52
-
-
68049099274
-
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
-
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2272-2283
-
-
Emery, P.1
Fleischmann, R.M.2
Moreland, L.W.3
Hsia, E.C.4
Strusberg, I.5
Durez, P.6
-
53
-
-
67449133560
-
Golimumab, a human antibody to tumour necrosisfactor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study
-
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosisfactor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68:789–96.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 789-796
-
-
Keystone, E.C.1
Genovese, M.C.2
Klareskog, L.3
Hsia, E.C.4
Hall, S.T.5
Miranda, P.C.6
-
54
-
-
84922564119
-
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis
-
Jansen JP, Buckley F, Dejonckheere F, Ogale S., Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102.
-
(2014)
Health Qual Life Outcomes
, vol.12
, pp. 102
-
-
Jansen, J.P.1
Buckley, F.2
Dejonckheere, F.3
Ogale, S.4
-
55
-
-
84930323836
-
Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis
-
Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP., Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 2015;21:409–23.
-
(2015)
J Manag Care Spec Pharm
, vol.21
, pp. 409-423
-
-
Buckley, F.1
Finckh, A.2
Huizinga, T.W.3
Dejonckheere, F.4
Jansen, J.P.5
-
56
-
-
33749363027
-
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
-
Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2817-2829
-
-
Maini, R.N.1
Taylor, P.C.2
Szechinski, J.3
Pavelka, K.4
Bröll, J.5
Balint, G.6
-
57
-
-
84897971056
-
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
-
Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803–9.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 803-809
-
-
Dougados, M.1
Kissel, K.2
Conaghan, P.G.3
Mola, E.M.4
Schett, G.5
Gerli, R.6
-
58
-
-
84956630876
-
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
-
Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75:1917–23.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 1917-1923
-
-
Kaneko, Y.1
Atsumi, T.2
Tanaka, Y.3
Inoo, M.4
Kobayashi-Haraoka, H.5
Amano, K.6
-
59
-
-
84864703156
-
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
-
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.
-
(2012)
N Engl J Med
, vol.367
, pp. 508-519
-
-
van Vollenhoven, R.F.1
Fleischmann, R.2
Cohen, S.3
Lee, E.B.4
García Meijide, J.A.5
Wagner, S.6
-
60
-
-
84874402383
-
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
-
van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.
-
(2013)
Arthritis Rheum
, vol.65
, pp. 559-570
-
-
van der Heijde, D.1
Tanaka, Y.2
Fleischmann, R.3
Keystone, E.4
Kremer, J.5
Zerbini, C.6
-
61
-
-
0031985832
-
The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials
-
Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P., The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36–43.
-
(1998)
J Rheumatol
, vol.25
, pp. 36-43
-
-
Ortiz, Z.1
Shea, B.2
Suarez-Almazor, M.E.3
Moher, D.4
Wells, G.A.5
Tugwell, P.6
-
62
-
-
0032200782
-
Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis
-
Pincus T., Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol. 1998;16:667–8.
-
(1998)
Clin Exp Rheumatol
, vol.16
, pp. 667-668
-
-
Pincus, T.1
-
63
-
-
1542359519
-
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review
-
Whittle SL, Hughes RA., Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–71.
-
(2004)
Rheumatology (Oxford)
, vol.43
, pp. 267-271
-
-
Whittle, S.L.1
Hughes, R.A.2
-
64
-
-
78650567202
-
Folate supplementation during methotrexate therapy for rheumatoid arthritis
-
Morgan SL, Baggott JE., Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(61):S102–S9.
-
(2010)
Clin Exp Rheumatol
, vol.28
, Issue.61
, pp. S102-S9
-
-
Morgan, S.L.1
Baggott, J.E.2
-
65
-
-
25844483861
-
Folate supplementation during methotrexate therapy for patients with psoriasis
-
Strober BE, Menon K., Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652–9.
-
(2005)
J Am Acad Dermatol
, vol.53
, pp. 652-659
-
-
Strober, B.E.1
Menon, K.2
-
66
-
-
84901712332
-
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
-
Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41:1049–60.
-
(2014)
J Rheumatol
, vol.41
, pp. 1049-1060
-
-
Shea, B.1
Swinden, M.V.2
Ghogomu, E.T.3
Ortiz, Z.4
Katchamart, W.5
Rader, T.6
-
67
-
-
0032835606
-
Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid
-
Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol. 1999;28:273–81.
-
(1999)
Scand J Rheumatol
, vol.28
, pp. 273-281
-
-
Suzuki, Y.1
Uehara, R.2
Tajima, C.3
Noguchi, A.4
Ide, M.5
Ichikawa, Y.6
-
68
-
-
0023785897
-
The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
-
Tishler M, Caspi D, Fishel B, Yaron M., The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906–9.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 906-909
-
-
Tishler, M.1
Caspi, D.2
Fishel, B.3
Yaron, M.4
-
69
-
-
0025887372
-
Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid
-
Joyce DA, Will RK, Hoffman DM, Laing B, Blackboum SJ., Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50:913–14.
-
(1991)
Ann Rheum Dis
, vol.50
, pp. 913-914
-
-
Joyce, D.A.1
Will, R.K.2
Hoffman, D.M.3
Laing, B.4
Blackboum, S.J.5
-
70
-
-
77951766263
-
New loci associated with kidney function and chronic kidney disease
-
Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42:376–84.
-
(2010)
Nat Genet
, vol.42
, pp. 376-384
-
-
Köttgen, A.1
Pattaro, C.2
Böger, C.A.3
Fuchsberger, C.4
Olden, M.5
Glazer, N.L.6
-
71
-
-
0035089876
-
Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient
-
Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.
-
(2001)
Arthritis Rheum
, vol.44
, pp. 339-342
-
-
Ito, S.1
Nakazono, K.2
Murasawa, A.3
Mita, Y.4
Hata, K.5
Saito, N.6
-
72
-
-
2342518217
-
Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis
-
Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N., Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:375–6.
-
(2004)
Clin Exp Rheumatol
, vol.22
, pp. 375-376
-
-
Hagiyama, H.1
Kubota, T.2
Komano, Y.3
Kurosaki, M.4
Watanabe, M.5
Miyasaka, N.6
-
73
-
-
84862269632
-
Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
-
Oketani M, Ido A, Uto H, Tsubouchi H., Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627–36.
-
(2012)
Hepatol Res
, vol.42
, pp. 627-636
-
-
Oketani, M.1
Ido, A.2
Uto, H.3
Tsubouchi, H.4
-
74
-
-
79960122345
-
Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis
-
Watanabe M, Banno S, Sasaki K, Naniwa T, Hayami Y, Ueda R., Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:144–9.
-
(2011)
Mod Rheumatol
, vol.21
, pp. 144-149
-
-
Watanabe, M.1
Banno, S.2
Sasaki, K.3
Naniwa, T.4
Hayami, Y.5
Ueda, R.6
-
75
-
-
0028939349
-
The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group
-
The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol. 1995;22:218–23.
-
(1995)
J Rheumatol
, vol.22
, pp. 218-223
-
-
-
76
-
-
0030000725
-
Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines
-
Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996;39:723–31.
-
(1996)
Arthritis Rheum
, vol.39
, pp. 723-731
-
-
-
77
-
-
4444369382
-
Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis
-
Kent PD, Luthra HS, Michet C, Jr. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol. 2004;31:1727–31.
-
(2004)
J Rheumatol
, vol.31
, pp. 1727-1731
-
-
Kent, P.D.1
Luthra, H.S.2
Michet, C.3
-
78
-
-
77649199610
-
Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients)
-
Cheung PP, Dougados M, Gossec L., Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients). Arthritis Care Res. 2010;62:323–34.
-
(2010)
Arthritis Care Res
, vol.62
, pp. 323-334
-
-
Cheung, P.P.1
Dougados, M.2
Gossec, L.3
-
79
-
-
84865862698
-
Perioperative management of disease modifying anti-rheumatic drugs: recommendations based on a meta-analysis
-
del Olmo L, Hemández B, Galindo-Izquierdo M, Tébar D, Balsa A, Carmona L., Perioperative management of disease modifying anti-rheumatic drugs: recommendations based on a meta-analysis. Rev Esp Cir Ortop Traumatol. 2012;56:393–412.
-
(2012)
Rev Esp Cir Ortop Traumatol
, vol.56
, pp. 393-412
-
-
del Olmo, L.1
Hemández, B.2
Galindo-Izquierdo, M.3
Tébar, D.4
Balsa, A.5
Carmona, L.6
-
80
-
-
72949115688
-
A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control
-
Loza E, Martinez-Lopez JA, Carmona L., A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol. 2009;27:856–62.
-
(2009)
Clin Exp Rheumatol
, vol.27
, pp. 856-862
-
-
Loza, E.1
Martinez-Lopez, J.A.2
Carmona, L.3
-
81
-
-
51549091222
-
The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis
-
Pieringer H, Stuby U, Biesenbach G., The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27:1217–20.
-
(2008)
Clin Rheumatol
, vol.27
, pp. 1217-1220
-
-
Pieringer, H.1
Stuby, U.2
Biesenbach, G.3
-
82
-
-
34047163955
-
Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?
-
Pieringer H, Stuby U, Biesenbach G., Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum. 2007;36:278–86.
-
(2007)
Semin Arthritis Rheum
, vol.36
, pp. 278-286
-
-
Pieringer, H.1
Stuby, U.2
Biesenbach, G.3
-
83
-
-
0026026468
-
Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate
-
Perhala RS, Wilke WS, Clough JD, Segal AM., Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum. 1991;34:146–52.
-
(1991)
Arthritis Rheum
, vol.34
, pp. 146-152
-
-
Perhala, R.S.1
Wilke, W.S.2
Clough, J.D.3
Segal, A.M.4
-
84
-
-
33644507068
-
Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery
-
Murata K, Yasuda T, Ito H, Yoshida M, Shimizu M, Nakajima T., Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol. 2006;16:14–19.
-
(2006)
Mod Rheumatol
, vol.16
, pp. 14-19
-
-
Murata, K.1
Yasuda, T.2
Ito, H.3
Yoshida, M.4
Shimizu, M.5
Nakajima, T.6
-
85
-
-
0027303840
-
Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis
-
Sany J, Anaya JM, Canovas F, Combe B, Jorgensen C, Saker S, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol. 1993;20:1129–32.
-
(1993)
J Rheumatol
, vol.20
, pp. 1129-1132
-
-
Sany, J.1
Anaya, J.M.2
Canovas, F.3
Combe, B.4
Jorgensen, C.5
Saker, S.6
-
86
-
-
0035089096
-
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery
-
Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60:214–17.
-
(2001)
Ann Rheum Dis
, vol.60
, pp. 214-217
-
-
Grennan, D.M.1
Gray, J.2
Loudon, J.3
Fear, S.4
-
87
-
-
0025767122
-
Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?
-
Bridges SL, Jr, López-Méndez A, Han KH, Tracy IC, Alarcón GS., Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol. 1991;18:984–8.
-
(1991)
J Rheumatol
, vol.18
, pp. 984-988
-
-
Bridges, S.L.1
López-Méndez, A.2
Han, K.H.3
Tracy, I.C.4
Alarcón, G.S.5
-
88
-
-
0029981838
-
Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy
-
Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE., Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics. 1996;19:207–10.
-
(1996)
Orthopedics
, vol.19
, pp. 207-210
-
-
Carpenter, M.T.1
West, S.G.2
Vogelgesang, S.A.3
Casey Jones, D.E.4
-
90
-
-
84959378744
-
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
-
Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 795-810
-
-
Götestam Skorpen, C.1
Hoeltzenbein, M.2
Tincani, A.3
Fischer-Betz, R.4
Elefant, E.5
Chambers, C.6
-
91
-
-
0015329455
-
Secretion of methotrexate into human milk
-
Johns DG, Rutherford LD, Leighton PC, Vogel CL., Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112:978–80.
-
(1972)
Am J Obstet Gynecol
, vol.112
, pp. 978-980
-
-
Johns, D.G.1
Rutherford, L.D.2
Leighton, P.C.3
Vogel, C.L.4
-
92
-
-
84923227527
-
Methotrexate use in a breastfeeding patient with rheumatoid arthritis
-
Thorne JC, Nadarajah T, Moretti M, Ito S., Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41:2332.
-
(2014)
J Rheumatol
, vol.41
, pp. 2332
-
-
Thorne, J.C.1
Nadarajah, T.2
Moretti, M.3
Ito, S.4
-
93
-
-
84897532072
-
Rheumatoid arthritis medications and lactation
-
Sammaritano LR, Bermas BL., Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol. 2014;26:354–60.
-
(2014)
Curr Opin Rheumatol
, vol.26
, pp. 354-360
-
-
Sammaritano, L.R.1
Bermas, B.L.2
-
94
-
-
0027174534
-
Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice
-
Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993;20:639–44.
-
(1993)
J Rheumatol
, vol.20
, pp. 639-644
-
-
Buchbinder, R.1
Hall, S.2
Sambrook, P.N.3
Champion, G.D.4
Harkness, A.5
Lewis, D.6
-
95
-
-
0030023020
-
Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis
-
Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR., Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:272–6.
-
(1996)
Arthritis Rheum
, vol.39
, pp. 272-276
-
-
Gutierrez-Urena, S.1
Molina, J.F.2
Garcia, C.O.3
Cuellar, M.L.4
Espinoza, L.R.5
-
96
-
-
22144458739
-
Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999
-
Kuitunen T, Maimström J, Palva E, Pettersson T., Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol. 2005;34:238–41.
-
(2005)
Scand J Rheumatol
, vol.34
, pp. 238-241
-
-
Kuitunen, T.1
Maimström, J.2
Palva, E.3
Pettersson, T.4
-
97
-
-
24944511275
-
Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years
-
Lim AY, Gaffney K, Scott DG., Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44:1051–5.
-
(2005)
Rheumatology (Oxford)
, vol.44
, pp. 1051-1055
-
-
Lim, A.Y.1
Gaffney, K.2
Scott, D.G.3
-
98
-
-
12344297751
-
The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions
-
Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF., The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44:61–6.
-
(2005)
Rheumatology (Oxford)
, vol.44
, pp. 61-66
-
-
Kinder, A.J.1
Hassell, A.B.2
Brand, J.3
Brownfield, A.4
Grove, M.5
Shadforth, M.F.6
-
99
-
-
1242342218
-
Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis
-
Saravanan V, Kelly CA., Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143–7.
-
(2004)
Rheumatology (Oxford)
, vol.43
, pp. 143-147
-
-
Saravanan, V.1
Kelly, C.A.2
-
100
-
-
0033964302
-
Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients
-
Imokawa S, Colby TV, Leslie KO, Helmers RA., Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373–81.
-
(2000)
Eur Respir J
, vol.15
, pp. 373-381
-
-
Imokawa, S.1
Colby, T.V.2
Leslie, K.O.3
Helmers, R.A.4
-
101
-
-
17044442903
-
Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group
-
Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356–64.
-
(1997)
Ann Intern Med
, vol.127
, pp. 356-364
-
-
Alarcón, G.S.1
Kremer, J.M.2
Macaluso, M.3
Weinblatt, M.E.4
Cannon, G.W.5
Palmer, W.R.6
-
102
-
-
0031440296
-
Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis
-
Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24:2299–303.
-
(1997)
J Rheumatol
, vol.24
, pp. 2299-2303
-
-
Ohosone, Y.1
Okano, Y.2
Kameda, H.3
Fujii, T.4
Hama, N.5
Hirakata, M.6
-
103
-
-
84887621217
-
Consensus statement for the diagnosis and treatment of drug-induced lung injuries
-
Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51:260–77.
-
(2013)
Respir Investig
, vol.51
, pp. 260-277
-
-
Kubo, K.1
Azuma, A.2
Kanazawa, M.3
Kameda, H.4
Kusumoto, M.5
Genma, A.6
-
104
-
-
0036745010
-
Predictors of infection in rheumatoid arthritis
-
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE., Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2294-2300
-
-
Doran, M.F.1
Crowson, C.S.2
Pond, G.R.3
O’Fallon, W.M.4
Gabriel, S.E.5
-
105
-
-
84865624563
-
Development and validation of a risk score for serious infection in patients with rheumatoid arthritis
-
Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL., Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2847–55.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2847-2855
-
-
Crowson, C.S.1
Hoganson, D.D.2
Fitz-Gibbon, P.D.3
Matteson, E.L.4
-
106
-
-
44649131357
-
Incidence of lymphoma in patients with rheumatoid arthritis: systematic review of the literature
-
Kaiser R., Incidence of lymphoma in patients with rheumatoid arthritis: systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87–93.
-
(2008)
Clin Lymphoma Myeloma
, vol.8
, pp. 87-93
-
-
Kaiser, R.1
-
107
-
-
84940487042
-
Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population
-
Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–71.
-
(2015)
J Rheumatol
, vol.42
, pp. 564-571
-
-
Hashimoto, A.1
Chiba, N.2
Tsuno, H.3
Komiya, A.4
Furukawa, H.5
Matsui, T.6
-
108
-
-
80052715653
-
Incidence of malignancy in Japanese patients with rheumatoid arthritis
-
Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31:1487–92.
-
(2011)
Rheumatol Int
, vol.31
, pp. 1487-1492
-
-
Yamada, T.1
Nakajima, A.2
Inoue, E.3
Tanaka, E.4
Taniguchi, A.5
Momohara, S.6
-
109
-
-
84939167646
-
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
-
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S., Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212–21.
-
(2015)
Arthritis Res Ther
, vol.17
, pp. 212-221
-
-
Simon, T.A.1
Thompson, A.2
Gandhi, K.K.3
Hochberg, M.C.4
Suissa, S.5
-
110
-
-
33644892763
-
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
-
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 692-701
-
-
Baecklund, E.1
Iliadou, A.2
Askling, J.3
Ekbom, A.4
Backlin, C.5
Granath, F.6
-
111
-
-
84906685237
-
Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients
-
Kameda T, Dobashi H, Miyatake N, Inoo M, Onishi I, Kurata N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66:1302–9.
-
(2014)
Arthritis Care Res (Hoboken)
, vol.66
, pp. 1302-1309
-
-
Kameda, T.1
Dobashi, H.2
Miyatake, N.3
Inoo, M.4
Onishi, I.5
Kurata, N.6
|